Leah Kuntz is a journalist who specializes in writing about psychiatric topics. She has written for Psychiatric Times and her work has also been featured in Drug Topics. Leah's articles cover a range of subjects including novel treatment development for serious mental illness, cognitive impairment in schizophrenia, and new therapies for postpartum depression and schizophrenia.
Preston is the artificial intelligence that powers the Intelligent Relations PR platform. Meet Preston
United States (National)
Not enough data
Leah's coverage is heavily focused on the healthcare and pharmaceutical industry, particularly in mental health research. Her articles often cite data and include expert commentary, indicating a preference for evidence-based information from authoritative sources.
Given Leah's focus on mental health topics and reliance on data-driven insights, she would likely be receptive to pitches that offer access to new research findings or interviews with experts who can provide valuable commentary based on empirical evidence. Additionally, she may be interested in exclusive insights regarding innovative treatments or therapeutic approaches related to mental health disorders.
While Leah does not have a specified geographic focus, her coverage appears global in scope as it encompasses advancements and research across various areas of mental health without being limited to specific regions.
This information evolves through artificial intelligence and human feedback. Improve this profile .
Do you want to be featured in a future Special Report? Check out our January theme!
By: Leah Kuntz
The FDA has granted Fast Track designation to posdinemab, a phosphorylated tau-directed monoclonal antibody being investigated for the treatment of patients with early Alzheimer disease.
Check out the positive topline results from a phase 2 dose finding trial evaluating N-methyl amisulpride (LB-102) in adult patients with acute schizophrenia.
Johnson & Johnson today announced that they will acquire all outstanding shares of Intra-Cellular Therapies, as well as their therapeutic pipeline, including lumateperone.
By: Leah Kuntz
The FDA grants Breakthrough Device Designation to Spear Bio’s pTau 217 blood test for Alzheimer disease.
Listen Key Takeaways Real Psychiatry conference offers in-person and virtual attendance, focusing on psychiatric advanced practice topics.
The lates update in lecanemab's journey: the FDA has accepted the BLA for lecanemab-irmb subcutaneous autoinjector for weekly maintenance dosing.
By: Leah Kuntz
Digital therapeutics may help improve negative symptoms associated with schizophrenia.
Check out these top tips for treating postpartum depression from the Real Psychiatry conference!
By: Leah Kuntz
The FDA has approved the supplemental New Drug Application for Spravato, the first and only monotherapy for adults with treatment-resistant depression.
(833) 317-6278 
